Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

On October 31, 2023 Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, reported that preclinical data from its oncogenic driver program targeting KRAS G12D, AFNT-212, will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting (Press release, Affini-T Therapeutics, OCT 31, 2023, View Source [SID1234636597]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Gene editing is a key piece of our overall strategy to develop precision immunotherapies for patients with hard-to-treat solid tumors," said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics. "Our data show that non-viral targeted knock-in engineered AFNT-212 T cells drive a robust coordinated CD4+ CD8+ T cell immune response against KRAS G12D mutated tumors with promising preclinical activity and tolerability, supporting the planned clinical development of our AFNT-212 T Cell Receptor-engineered therapy. We look forward to presenting these findings at SITC (Free SITC Whitepaper)."

Poster presentation details are as follows:

Title: Directing a high avidity KRAS G12D-specific TCR engineered with a CD8αβ co-receptor and chimeric cytokine receptor using non-viral knock-in enhances anti-tumor responses
Abstract no: 355
Presenting Author: Ankit Gupta, Ph.D., Senior Director, Gene Editing, Affini-T Therapeutics
Date/Time: Friday, November 3, 2023, 12:00 pm – 1:30 pm and 5:10 pm – 6:40 pm PT

Title: Non-viral targeted knock-in of a KRAS G12D specific TCR, CD8αβ, and chimeric cytokine receptor in the TRAC locus outperforms lentiviral-based engineering of T cells
Abstract no: 1223
Presenting Author: Allison P. Drain, Ph.D., Senior Scientist, Synthetic Biology, Affini-T Therapeutics
Date/Time: Friday, November 3, 2023, 12:00 pm – 1:30 pm and 5:10 pm – 6:40 pm PT